Install
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
- 86articles · 30d
- 10+ hour agolatest article
- Aug 14, 2026earliest in window
- 94%with images
- 229avg words
- BI 59
- HTH 47
- economy business and finance 42
- FIB 27
- health 24
- HW 24
- science and technology 18
- SCT 6
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Exec on Execs: Identifying the Gaps | PharmExec
2+ week, 6+ day ago (58+ words) Exec on Execs: Identifying the Gaps Pharmaceutical Executive The Operational Reality of Reshoring Pharma Manufacturing: Q&A with Rohit Tripathi Your Questions Answered: What This Week's Rare Disease and Specialty Drug News Tells Us About Where the Industry Is Heading…...
Exec on Execs: Persistent Unmet Needs | PharmExec
5+ day, 22+ hour ago (56+ words) Exec on Execs: Persistent Unmet Needs Pharmaceutical Executive Pharmaceutical Executive Daily: Novartis and BMS Halt CAR-T Trials Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTech Partnership, RedHill Acquires Commercialization Rights to Rebyota & Clenpiq How New Therapies…...
FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer
2+ week, 3+ day ago (411+ words) The FDA has approved Revolution Medicines' daraxonrasib, the first RAS-directed therapy for previously treated metastatic pancreatic adenocarcinoma, based on a phase 3 trial showing a survival benefit over chemotherapy. The FDA has approved daraxonrasib (brand name Rasonque) for adults with metastatic…...